– Brand: ViennaLab – Germany
– Model: KRAS StripAssay®
KRAS Strip Assay
The easy way to optimize colorectal cancer therapies using established innovations in diagnostics.
Metastatic colorectal cancer Assay. Key to the best therapy.
Modern cancer therapies can efficiently combat metastatic colorectal cancer. The best results are achieved when a specific type of cancer is matched with its appropriate therapy. For metastatic colorectal cancer monoclonal anti- body therapies that target EGFR (such as cetuximab and panitumumab) work exceptionally well in many cases. But not in all.
Certain mutations in the KRAS gene prevent the therapeutic success of therapies that target EGFR.
Epidermal Growth Factor (EGF) activates cell prolifera-tion by binding to the EGF-Receptor (EGFR). This triggers a signal transduction pathway that includes the KRAS protein. Inhibiting the EGFR with monoclonal antibodies prevents the activation of the relevant signal transduction right at the start of the pathway. However this only works if other parts of that pathway are not permanently acti- vated regardless of the EGF-signal. Mutations in KRAS can cause this kind of activation that renders anti-EGFR therapies ineffective.
The KRAS StripAssay® offers an easy way to identify the most relevant mutations in the KRAS gene. Established innovations in diagnostics by ViennaLab thus help to optimize metastatic colorectal cancer therapies.
The ViennaLab KRAF StripAssay® combines all these requirements. Better than any other assay currently on the market.
The ViennaLab KRAS StripAssay® is based on reverse-hybridization of biotinylated PCR products combines probes for mutations and controls in a parallel array of allele-specific oligonucleotides works with immobilized oligos on a teststrip shows mutations by enzymatic reaction already visible to the naked eye.